Minerva Neurosciences, Inc
NERVMinerva Neurosciences, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for neuropsychiatric and neurological disorders. The company's pipeline includes treatments targeting conditions such as schizophrenia, cognitive impairment, and other central nervous system disorders. Minerva aims to address unmet medical needs through novel drug candidates and has a focus on advancing neuroscience research.
Company News
Minerva Neurosciences secured a $200 million funding agreement to support its Phase 3 trial for roluperidone, a drug targeting negative symptoms of schizophrenia. The funding includes immediate $80 million and potential additional tranches, with investors like Vivo Capital and Janus Henderson participating.
The schizophrenia market is expected to grow significantly by 2034, driven by rising disease prevalence, expanding approved therapies, and the anticipated launch of new treatments such as Olanzapine LAI, Iclepertin, Ulotaront, and Brilaroxazine.
Cartesian Therapeutics announced positive top-line results from its mid-stage study evaluating lead candidate Descartes-08 in patients with generalized myasthenia gravis. The study achieved its primary endpoint, with 71% of MG patients treated with Descartes-08 showing significant improvements in MG Composite score compared to 25% with placebo.
Roche (RHHBY) obtains approval for the subcutaneous formulation of relapsing multiple sclerosis drug Ocrevus in Europe. In addition, a review of the company's MAA for gene therapy, Elevidys, is also underway.
Bristol Myers (BMY) wins FDA approval for Krazati, in combination with Erbitux, as a targeted treatment option for adult patients with KRASG12C-mutated locally advanced or metastatic colorectal cancer.
